AU2002243439A1 - Fatty acid synthase inhibitors - Google Patents

Fatty acid synthase inhibitors

Info

Publication number
AU2002243439A1
AU2002243439A1 AU2002243439A AU2002243439A AU2002243439A1 AU 2002243439 A1 AU2002243439 A1 AU 2002243439A1 AU 2002243439 A AU2002243439 A AU 2002243439A AU 2002243439 A AU2002243439 A AU 2002243439A AU 2002243439 A1 AU2002243439 A1 AU 2002243439A1
Authority
AU
Australia
Prior art keywords
fatty acid
acid synthase
synthase inhibitors
inhibitors
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002243439A
Inventor
Jeffrey M. Axten
Robert A. Daines
Israil Pendrak
Wei Peng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002243439A1 publication Critical patent/AU2002243439A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
AU2002243439A 2000-11-17 2001-11-16 Fatty acid synthase inhibitors Abandoned AU2002243439A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24964700P 2000-11-17 2000-11-17
US60/249,647 2000-11-17
PCT/US2001/051330 WO2002055661A2 (en) 2000-11-17 2001-11-16 Fatty acid synthase inhibitors

Publications (1)

Publication Number Publication Date
AU2002243439A1 true AU2002243439A1 (en) 2002-07-24

Family

ID=22944400

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002243439A Abandoned AU2002243439A1 (en) 2000-11-17 2001-11-16 Fatty acid synthase inhibitors

Country Status (2)

Country Link
AU (1) AU2002243439A1 (en)
WO (1) WO2002055661A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075077A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Piperidine derivatives for the treatment of obesity
TW200833663A (en) * 2006-12-21 2008-08-16 Astrazeneca Ab Therapeutic agents
EP2615918A4 (en) * 2010-09-17 2014-01-29 Glaxosmithkline Ip Dev Ltd Fatty acid synthase inhibitors
CN105492008B (en) 2013-03-13 2020-11-27 福马治疗股份有限公司 Compounds and compositions for inhibition of FASN
WO2017207556A2 (en) * 2016-05-30 2017-12-07 Technische Universität München Urea motif containing compounds and derivatives thereof as antibacterial drugs
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Also Published As

Publication number Publication date
WO2002055661A3 (en) 2003-02-13
WO2002055661A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
AU2001270200A1 (en) Fatty acid synthase inhibitors
AU2001278986A1 (en) 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
AU2001236052A1 (en) Urease inhibitors
AU2001281059A1 (en) Fatty acid synthase inhibitors
AU2001280167A1 (en) Novel propenohydroxamic acid derivatives
AU2002222627A1 (en) Tak1 inhibitors
AU7526901A (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
IL148324A0 (en) Fatty acid synthase inhibitors
AU7961300A (en) Kainic acid neurocytotoxicity inhibitors
AU2001271531A1 (en) Fatty acid synthase inhibitors
AU2002224550A1 (en) Corrosion inhibitors
AU2002243439A1 (en) Fatty acid synthase inhibitors
AU2001274940A1 (en) Fatty acid synthase inhibitors
IL151250A0 (en) Difluorobutyric acid metalloprotease inhibitors
GB0030284D0 (en) Enzyme inhibitors
AU6925500A (en) Fatty acid synthase inhibitors
AU2001271718A1 (en) Fatty acid synthase inhibitors
AU6926500A (en) Fatty acid synthase inhibitors
AU2001291160A1 (en) Fatty acid synthase inhibitors
AU2001284705A1 (en) Fatty acid synthase inhibitors
AUPQ851000A0 (en) Rapid fatty acid delivery
AU2001268853A1 (en) Biocatalyst inhibitors
AU2001269121A1 (en) Substituted amidoalkyl-uracils as parp inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase